Outer membrane vesicles derived from gut microbiota mediate tubulointerstitial inflammation: a potential new mechanism for diabetic kidney disease

被引:18
作者
Chen, Pei Pei [1 ]
Zhang, Jia Xiu [1 ]
Li, Xue Qi [1 ]
Li, Liang [1 ,2 ]
Wu, Qin Yi [1 ]
Liu, Liang
Wang, Gui Hua [1 ]
Ruan, Xiong Zhong [3 ]
Ma, Kun Ling [1 ,4 ]
机构
[1] Southeast Univ, Inst Nephrol, Sch Med, Zhongda Hosp, Nanjing 210009, Peoples R China
[2] Shandong First Med Univ, Peoples Hosp, Jinan 271100, Shandong, Peoples R China
[3] UCL, Sch Med, Dept Renal Med, John Moorhead Res Lab, Royal Free Campus, London NW3 2PF, England
[4] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Nephrol, Hangzhou 310003, Peoples R China
来源
THERANOSTICS | 2023年 / 13卷 / 12期
基金
中国国家自然科学基金;
关键词
diabetic kidney disease; renal tubulointerstitial inflammation; gut microbiota; outer membrane vesicles; caspase-11; pathway; LPS; NEPHROPATHY; PROGRESSION; SULFATE;
D O I
10.7150/thno.84650
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Rationale: Chronic tubulointerstitial inflammation is a common pathological process in diabetic kidney disease (DKD). However, its underlying mechanism is largely unknown. This study aims at investigating the role of gut microbiota-derived outer membrane vesicles (OMVs) in tubulointerstitial inflammation in DKD.Methods: Gut microbiota in diabetes mellitus rats was manipulated by microbiota depletion and fecal microbiota transplantation to explore its role in tubulointerstitial inflammation. To check the direct effects of OMVs, fecal bacterial extracellular vesicles (fBEVs) were administrated to mice orally and HK-2 cells in vitro. For mechanistic investigations, HK-2 cells were treated with small interfering RNA against caspase-4 and fBEVs pre-neutralized by polymyxin B.Results: By performing gut microbiota manipulation, it was confirmed that gut microbiota mediated tubulointerstitial inflammation in DKD. In diabetic rats, gut microbiota-derived OMVs were increased and were clearly detected in distant renal tubulointerstitium. Diabetic fBEVs directly administered by gavage translocated into tubular epithelial cells and induced tubulointerstitial inflammation and kidney injury. In vitro, OMVs were internalized through various endocytic pathways and triggered cellular inflammatory response. Mechanistically, it was revealed that OMVs-derived lipopolysaccharide induced tubular inflammation, which was mediated by the activation of the caspase-11 pathway.Conclusions: Increased OMVs due to dysbiosis translocated through leaky gut barrier into distant tubulointerstitium and induced cellular inflammation and renal tubulointerstitial injury in DKD. These findings enrich the mechanism understanding of how gut microbiota and its releasing OMVs influence the development and progression of kidney disease.
引用
收藏
页码:3988 / 4003
页数:16
相关论文
共 30 条
  • [21] Alzheimer's Disease-Derived Outer Membrane Vesicles Exacerbate Cognitive Dysfunction, Modulate the Gut Microbiome, and Increase Neuroinflammation and Amyloid-β Production
    Wei, Shouchao
    Ma, Xiaochen
    Chen, Yating
    Wang, Junjun
    Hu, Li
    Liu, Zhou
    Mo, Lang
    Zhou, Ning
    Chen, Wenrong
    Zhu, He
    Yan, Shian
    MOLECULAR NEUROBIOLOGY, 2025, 62 (04) : 5109 - 5132
  • [22] Probiotic Escherichia coli Nissle 1917-derived outer membrane vesicles modulate the intestinal microbiome and host gut-liver metabolome in obese and diabetic mice
    Shi, Jun
    Ma, Dongxue
    Gao, Shanhu
    Long, Fei
    Wang, Xin
    Pu, Xingyu
    Cannon, Richard D.
    Han, Ting-Li
    FRONTIERS IN MICROBIOLOGY, 2023, 14
  • [23] Therapeutic potential of urine exosomes derived from rats with diabetic kidney disease
    Mishra, Deendayal Das
    Sahoo, Biswajit
    Maurya, Pramod Kumar
    Sharma, Rajni
    Varughese, Santosh
    Prasad, Narayan
    Tiwari, Swasti
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [24] Quantitative, Targeted Analysis of Gut Microbiota Derived Metabolites Provides Novel Biomarkers of Early Diabetic Kidney Disease in Type 2 Diabetes Mellitus Patients
    Balint, Lavinia
    Socaciu, Carmen
    Socaciu, Andreea Iulia
    Vlad, Adrian
    Gadalean, Florica
    Bob, Flaviu
    Milas, Oana
    Cretu, Octavian Marius
    Suteanu-Simulescu, Anca
    Glavan, Mihaela
    Ienciu, Silvia
    Mogos, Maria
    Jianu, Dragos Catalin
    Petrica, Ligia
    BIOMOLECULES, 2023, 13 (07)
  • [25] Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease
    Heerspink, Hiddo J. L.
    Perco, Paul
    Mulder, Skander
    Leierer, Johannes
    Hansen, Michael K.
    Heinzel, Andreas
    Mayer, Gert
    DIABETOLOGIA, 2019, 62 (07) : 1154 - 1166
  • [26] Roles of Mitochondrial Dysfunction in Diabetic Kidney Disease: New Perspectives from Mechanism to Therapy
    Yang, Yichen
    Liu, Jiahui
    Shi, Qiling
    Guo, Buyu
    Jia, Hanbing
    Yang, Yuxuan
    Fu, Songbo
    BIOMOLECULES, 2024, 14 (06)
  • [27] Membrane Vesicles Derived from Gut Microbiota and Probiotics: Cutting-Edge Therapeutic Approaches for Multidrug-Resistant Superbugs Linked to Neurological Anomalies
    Srivastava, Prakhar
    Kim, Kwang-sun
    PHARMACEUTICS, 2022, 14 (11)
  • [28] Extracellular vesicles derived from mesenchymal stem cells alleviate renal fibrosis via the miR-99b-5p/mTOR/autophagy axis in diabetic kidney disease
    Li, Rongrong
    Tao, Hongyan
    Pan, Kai
    Li, Rui
    Guo, Zhikun
    Chen, Xiaoniao
    Li, Zongjin
    STEM CELL RESEARCH & THERAPY, 2025, 16 (01)
  • [29] The potential mechanism of Liu-Wei-Di-Huang Pills in treatment of type 2 diabetic mellitus: from gut microbiota to short-chain fatty acids metabolism
    Yi, Zi-yang
    Chen, Lin
    Wang, Yan
    He, Dan
    Zhao, Di
    Zhang, Shui-han
    Yu, Rong
    Huang, Jian-hua
    ACTA DIABETOLOGICA, 2022, 59 (10) : 1295 - 1308
  • [30] Small extracellular vesicles-shuttled miR-23a-3p from mesenchymal stem cells alleviate renal fibrosis and inflammation by inhibiting KLF3/STAT3 axis in diabetic kidney disease
    Li, Qianhua
    Liu, Jiaxi
    Su, Rongyun
    Zhen, Junhui
    Liu, Xiangchun
    Liu, Gang
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 139